NCT07153705Not yet recruiting
OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 4 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 32 (estimated)
- First submitted
- 26 Aug 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 1 Apr 2026
- Lead sponsor
- Beihua Kong
- Diseases
- Ovarian cancer
- NCT number
- NCT07153705
What you commit to
- Study type: Observational
- Planned participants: 32
- From 1 Sept 2025 to the primary completion date, 1 Apr 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have received any treatment for ovarian cancer;
- Patients receiving neoadjuvant therapy;
Other illness
- Have had other malignant tumors within the last five years;
- Combined with other malignant tumors;
Other
- Benign ovarian mass;
- Non-primary ovarian tumors;
- Pregnancy.
Who the study is looking for
- Women over 18 years old;
- Pathologically confirmed as stage I-IV primary epithelial ovarian malignant tumor;
- ECOG \< 2;
- The expected survival period exceeds 6 months;
- CA125 ≤ 35 U/ml before initial treatment;
- Undergo surgery and adjuvant chemotherapy;
- The period between diagnosis and enrollment does not exceed 8 weeks;
- Be willing to provide blood samples for OCS testing during the research process;
- Sign the informed consent form.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.